PET imaging in patients with brain metastasis-report of the RANO/PET group.
暂无分享,去创建一个
Ian Law | Karl-Josef Langen | Susan Chang | Matthias Preusser | Michael Weller | Stephanie E Combs | Norbert Galldiks | Riccardo Soffietti | Susan M. Chang | Peter Forsyth | Michelle M Kim | Julian Schwarting | M. Weller | N. Galldiks | K. Langen | N. Albert | J. Tonn | R. Soffietti | M. Preusser | M. Chamberlain | W. Pope | I. Law | S. Combs | É. Le Rhun | P. Forsyth | Michelle M. Kim | Marc Chamberlain | Whitney Pope | Nathalie L Albert | Jörg C Tonn | Emilie Le Rhun | J. Schwarting | J. Schwarting
[1] Axel Hoos,et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.
[2] A. Akabane,et al. Differentiation of Brain Tumor Recurrence from Post-Radiotherapy Necrosis with 11C-Methionine PET: Visual Assessment versus Quantitative Assessment , 2015, PloS one.
[3] R. Sweeney,et al. PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[4] Gereon R. Fink,et al. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-l-tyrosine PET , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[5] J. Landsberg,et al. Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases. , 2016, Neuro-Oncology.
[6] F. Alongi,et al. 18F-Sodium Fluoride PET-CT for the Assessment of Brain Metastasis from Lung Adenocarcinoma. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[7] Yang Lu. FDG and (82)Rb PET/MRI features of brain metastasis of breast cancer. , 2015, Clinical nuclear medicine.
[8] N. Shah,et al. Radiation injury vs. recurrent brain metastasis: combining textural feature radiomics analysis and standard parameters may increase 18F-FET PET accuracy without dynamic scans , 2017, European Radiology.
[9] T Greitz,et al. Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. , 1983, Journal of computer assisted tomography.
[10] P. Brown,et al. Brain metastases: fractionated whole-brain radiotherapy. , 2018, Handbook of clinical neurology.
[11] Y Kanai,et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I–III nonsmall cell lung cancer , 2008, British Journal of Cancer.
[12] R. Baum,et al. Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen. , 2018, The British journal of radiology.
[13] Emily B. Ehlerding,et al. PET Imaging of Receptor Tyrosine Kinases in Cancer , 2018, Molecular Cancer Therapeutics.
[14] Aliasgar Moiyadi,et al. Common malignant brain tumors: can 18F-FDG PET/CT aid in differentiation? , 2017, Nuclear medicine communications.
[15] Gereon R. Fink,et al. Combined FET PET/MRI radiomics differentiates radiation injury from recurrent brain metastasis , 2018, NeuroImage: Clinical.
[16] Steven N. Kalkanis,et al. The role of imaging in the management of progressive glioblastoma , 2014, Journal of Neuro-Oncology.
[17] Karl-Josef Langen,et al. Neuro-oncology: Amino acid PET for brain tumours — ready for the clinic? , 2016, Nature Reviews Neurology.
[18] N. Sibson,et al. Glial Activation in the Early Stages of Brain Metastasis: TSPO as a Diagnostic Biomarker , 2014, The Journal of Nuclear Medicine.
[19] Thomas Czech,et al. Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[20] N. Galldiks,et al. From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors? , 2015, Neuro-oncology.
[21] Naoya Hashimoto,et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. , 2015, The Lancet. Oncology.
[22] Wolfgang A. Weber,et al. O-(2-[18F]Fluoroethyl)-l-tyrosine and l-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study , 2000, European Journal of Nuclear Medicine.
[23] A. Bozzao,et al. Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis , 2011, Radiation oncology.
[24] K. Zilles,et al. Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. , 2003, Nuclear medicine and biology.
[25] N. Albert,et al. Early static 18F-FET-PET scans have a higher accuracy for glioma grading than the standard 20–40 min scans , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[26] Martin Bendszus,et al. Response assessment criteria for brain metastases: proposal from the RANO group. , 2015, The Lancet. Oncology.
[27] Maximilian Niyazi,et al. Prognostic Significance of Dynamic 18F-FET PET in Newly Diagnosed Astrocytic High-Grade Glioma , 2015, The Journal of Nuclear Medicine.
[28] T. Tamiya,et al. Correlation of l-methyl-11C-methionine (MET) uptake with l-type amino acid transporter 1 in human gliomas , 2010, Journal of Neuro-Oncology.
[29] Whitney B Pope,et al. Brain metastases: neuroimaging. , 2018, Handbook of clinical neurology.
[30] N. Albert,et al. Detection of Cerebrospinal Fluid Dissemination of Recurrent Glioblastoma Using TSPO-PET With 18F-GE-180. , 2018, Clinical nuclear medicine.
[31] M. Weller,et al. Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab. , 2016, Neuro-oncology.
[32] Low positive yield from routine inclusion of the brain in whole-body 18F-FDG PET/CT imaging for noncerebral malignancies: results from a large population study , 2013, Nuclear medicine communications.
[33] K. Langen,et al. Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[34] Val J Lowe,et al. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. , 2013, Neuro-oncology.
[35] J. Mukherjee,et al. 11C-l-Methionine Positron Emission Tomography in the Clinical Management of Cerebral Gliomas , 2007, Molecular Imaging and Biology.
[36] Rajiv Kumar,et al. Detection of brain metastasis with 68Ga-labeled PSMA ligand PET/CT: a novel radiotracer for imaging of prostate carcinoma. , 2015, Clinical nuclear medicine.
[37] S. Mittal,et al. Comparison of Amino Acid Positron Emission Tomographic Radiotracers for Molecular Imaging of Primary and Metastatic Brain Tumors , 2014, Molecular imaging.
[38] N. Galldiks,et al. 18F-FET PET Uptake Characteristics in Patients with Newly Diagnosed and Untreated Brain Metastasis , 2017, The Journal of Nuclear Medicine.
[39] M. Weller,et al. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake. , 2016, Neuro-oncology.
[40] A. Buck,et al. 68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate? , 2016, Neuro-oncology.
[41] Wolfgang A Weber,et al. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. , 2011, International journal of radiation oncology, biology, physics.
[42] Jacques Darcourt,et al. Study of LAT1 Expression in Brain Metastases: Towards a Better Understanding of the Results of Positron Emission Tomography Using Amino Acid Tracers , 2016, PloS one.
[43] G. Barnett,et al. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery , 2001, International journal of cancer.
[44] N. Tomura,et al. Differentiation between Treatment-Induced Necrosis and Recurrent Tumors in Patients with Metastatic Brain Tumors: Comparison among 11C-Methionine-PET, FDG-PET, MR Permeability Imaging, and MRI-ADC—Preliminary Results , 2017, American Journal of Neuroradiology.
[45] Karl-Josef Langen,et al. O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. , 2006, Nuclear medicine and biology.
[46] M. Wiesmann,et al. O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis , 2017, Neuro-oncology.
[47] O. Belohlávek,et al. Brain metastases after stereotactic radiosurgery using the Leksell gamma knife: can FDG PET help to differentiate radionecrosis from tumour progression? , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[48] P Van Tassel,et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. , 2000, Radiology.
[49] Karl-Josef Langen,et al. Update on amino acid PET of brain tumours , 2018, Current opinion in neurology.
[50] Fridtjof Nüsslin,et al. “Radio-oncomics” , 2017, Strahlentherapie und Onkologie.
[51] H. Herzog,et al. Role of O-(2-18F-Fluoroethyl)-l-Tyrosine PET for Differentiation of Local Recurrent Brain Metastasis from Radiation Necrosis , 2012, The Journal of Nuclear Medicine.
[52] Edward M. Hsiao,et al. Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis , 2011, Journal of Neuro-Oncology.
[53] N. Galldiks,et al. Amino acid PET in neuro-oncology: applications in the clinic , 2017, Expert review of anticancer therapy.
[54] J. Mountz,et al. Brain tumors. , 2012, Seminars in nuclear medicine.
[55] I. Okayasu,et al. High expression of L-type amino acid transporter 1 (LAT1) predicts poor prognosis in pancreatic ductal adenocarcinomas , 2012, Journal of Clinical Pathology.
[56] Jill S Barnholtz-Sloan,et al. Brain metastases: epidemiology. , 2018, Handbook of clinical neurology.
[57] R. Baum,et al. Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for Glioma Grading: Assessment of Individual Probability of Malignancy , 2011, Clinical nuclear medicine.
[58] Otto Muzik,et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.
[59] Gereon R. Fink,et al. Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy , 2016, Neuro-oncology.
[60] K. Peck,et al. A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation. , 2016, Neuro-oncology.
[61] Alexander Radbruch,et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO) , 2017, Neuro-oncology.
[62] Nadim Jon Shah,et al. Advances in neuro-oncology imaging , 2017, Nature Reviews Neurology.
[63] J. Steinbach,et al. From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo , 2018, Oncotarget.
[64] J. McConathy,et al. Radiolabeled Amino Acids for Oncologic Imaging , 2013, The Journal of Nuclear Medicine.
[65] Otto Muzik,et al. Differentiation of Glioblastomas from Metastatic Brain Tumors by Tryptophan Uptake and Kinetic Analysis: A Positron Emission Tomographic Study with Magnetic Resonance Imaging Comparison , 2013, Molecular imaging.
[66] A. Buck,et al. CXCR4-directed theranostics in oncology and inflammation , 2018, Annals of Nuclear Medicine.
[67] Gereon R Fink,et al. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. , 2015, Neuro-oncology.
[68] Eudocia Q Lee,et al. Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. , 2018, The Lancet. Oncology.
[69] T. Wibmer,et al. Brain metastasis in lung cancer , 2010, Nuklearmedizin.
[70] D. Hafler,et al. Prospects of immune checkpoint modulators in the treatment of glioblastoma , 2015, Nature Reviews Neurology.
[71] N. Albert,et al. Suspected recurrence of brain metastases after focused high dose radiotherapy: can [18F]FET- PET overcome diagnostic uncertainties? , 2016, Radiation Oncology.
[72] Ian Law,et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. , 2016, Neuro-oncology.
[73] Shigeaki Higashiyama,et al. Diagnostic Accuracy of 11C-Methionine PET for Differentiation of Recurrent Brain Tumors from Radiation Necrosis After Radiotherapy , 2008, Journal of Nuclear Medicine.
[74] F. Mottaghy,et al. The Use of O-(2-18F-Fluoroethyl)-l-Tyrosine PET for Treatment Management of Bevacizumab and Irinotecan in Patients with Recurrent High-Grade Glioma: A Cost-Effectiveness Analysis , 2013, The Journal of Nuclear Medicine.
[75] Francesco Scopinaro,et al. Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[76] T. Tamiya,et al. Relation of LAT1/4F2hc expression with pathological grade, proliferation and angiogenesis in human gliomas , 2012, BMC Clinical Pathology.
[77] M. Dziuk,et al. Brain metastases in patient with prostate cancer found in 18F-choline PET/CT. , 2015, Nuclear medicine review. Central & Eastern Europe.
[78] P. Bartenstein,et al. Dynamic 18F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients , 2014, The Journal of Nuclear Medicine.
[79] Jason S. Lewis,et al. Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab) , 2018, Scientific Reports.
[80] K. Ohata,et al. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? , 2003, Journal of neurosurgery.
[81] Uwe Haberkorn,et al. Intra-individual comparison of ¹⁸F-FET and ¹⁸F-DOPA in PET imaging of recurrent brain tumors. , 2014, Neuro-oncology.
[82] M Schwaiger,et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[83] K. Takakura,et al. Differentiation of the Radiation-Induced Necrosis and Tumor Recurrence after Gamma Knife Radiosurgery for Brain Metastases: Importance of Multi-Voxel Proton MRS , 2005, Minimally invasive neurosurgery : MIN.
[84] Steven P. Rowe,et al. Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications , 2018, Annals of Nuclear Medicine.
[85] Junia C Costa,et al. Impact of [18F]-fluoro-ethyl-tyrosine PET imaging on target definition for radiation therapy of high-grade glioma. , 2015, Neuro-oncology.
[86] M. Weller,et al. Letter to the Editor: “The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline” [J Neurooncol 2014; 118:435–460] , 2014, Journal of Neuro-Oncology.
[87] Karl-Josef Langen,et al. Cost-Effectiveness Analysis of Amino Acid PET–Guided Surgery for Supratentorial High-Grade Gliomas , 2012, The Journal of Nuclear Medicine.
[88] J. Menten,et al. Non-invasive grading of brain tumours using dynamic amino acid PET imaging : does it work for 11C-Methionine? , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[89] E. Kasper,et al. Diagnostic Accuracy of PET, SPECT, and Arterial Spin-Labeling in Differentiating Tumor Recurrence from Necrosis in Cerebral Metastasis after Stereotactic Radiosurgery , 2015, American Journal of Neuroradiology.
[90] S. Yomo,et al. Prospective study of 11C–methionine PET for distinguishing between recurrent brain metastases and radiation necrosis: limitations of diagnostic accuracy and long-term results of salvage treatment , 2017, BMC Cancer.
[91] Ian Law,et al. The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy , 2016, NeuroImage: Clinical.
[92] Martin Sill,et al. Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response , 2016, Clinical Cancer Research.
[93] R. Kefford,et al. Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases , 2016, British Journal of Cancer.
[94] Esin Cakan,et al. The use of 18F-FDG PET ratios in the differential diagnosis of common malignant brain tumors. , 2015, Clinical imaging.
[95] A. Inno,et al. 18F-NaF PET/CT Imaging of Brain Metastases. , 2016, Clinical nuclear medicine.
[96] F. Kreth,et al. The role of surgery for brain metastases from solid tumors. , 2018, Handbook of clinical neurology.
[97] Ricardo J. Komotar,et al. Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality? , 2013, Journal of Neuro-Oncology.
[98] E. Hsiao,et al. Cerebellar Metastases From Prostate Cancer on 68Ga-PSMA PET/CT. , 2017, Clinical nuclear medicine.
[99] M. Ahluwalia,et al. Systemic therapy for brain metastases. , 2018, Handbook of clinical neurology.
[100] G. Jin,et al. Comparison of Gadolinium-enhanced MRI and 18FDG PET/PET-CT for the diagnosis of brain metastases in lung cancer patients: A meta-analysis of 5 prospective studies , 2017, Oncotarget.
[101] R. Avery,et al. Incidence of Brain Metastases on Follow-up 18F-FDG PET/CT Scans of Non–Small Cell Lung Cancer Patients: Should We Include the Brain? , 2017, The Journal of Nuclear Medicine Technology.
[102] J. Mountz,et al. Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: A Pilot Study , 2018, Front. Oncol..
[103] T. Lammers,et al. Imaging Nanomedicine-Based Drug Delivery: a Review of Clinical Studies , 2018, Molecular Imaging and Biology.
[104] J. Sarkaria,et al. The role of LAT1 in 18F-DOPA uptake in malignant gliomas , 2012, Journal of Neuro-Oncology.
[105] S. Steinberg,et al. ANG1005 for breast cancer brain metastases: correlation between 18F-FLT–PET after first cycle and MRI in response assessment , 2016, Breast Cancer Research and Treatment.
[106] M. Weller,et al. PET imaging in patients with meningioma—report of the RANO/PET Group , 2017, Neuro-oncology.
[107] Michael E. Phelps,et al. 18F-FDOPA PET for Differentiating Recurrent or Progressive Brain Metastatic Tumors from Late or Delayed Radiation Injury After Radiation Treatment , 2014, The Journal of Nuclear Medicine.
[108] Keigo Endo,et al. Transport of 3-Fluoro-l-α-Methyl-Tyrosine by Tumor-Upregulated L-Type Amino Acid Transporter 1: A Cause of the Tumor Uptake in PET , 2012, The Journal of Nuclear Medicine.
[109] D. Fielding,et al. Non‐small cell lung cancer brain metastasis screening in the era of positron emission tomography‐CT staging: Current practice and outcomes , 2018, Journal of medical imaging and radiation oncology.